Wang Huan, Zheng Weijian, Fang Weiping, Meng Gaige, Zhang Lei, Zhou Yannan, Gu Erwei, Liu Xuesheng
Department of Anesthesiology, the First Affiliated Hospital of Anhui Medical University, No. 218 Jixi Road, Hefei, Anhui, 230022, People's Republic of China.
J Cardiothorac Surg. 2018 Oct 17;13(1):109. doi: 10.1186/s13019-018-0794-6.
We sought to evaluate the safety, efficacy, and cost-effectiveness of intraoperative blood salvage (IBS) in off-pump coronary artery bypass grafting (OPCABG) surgery with different amount of bleeding.
We retrospectively reviewed the medical records of 321 patients who underwent OPCABG between December 2012 and December 2016 at our hospital. Patients treated with IBS or allogeneic blood (AB) transfusions were divided into three groups depending on the amount of bleeding respectively: IBS1 or AB1 group (400-600 ml); IBS2 or AB2 group (600-1000 ml); IBS3 or AB3 group (1000-1500 ml). The intraoperative and postoperative conditions, blood transfusion volume, clinical and hematological outcomes, and total blood transfusion cost were examined.
The amount of allogeneic red blood cell (RBC) transfusion in the IBSs groups were significantly lower than that in the ABs groups (P < 0.01). Furthermore, drainage volume 24 h post-surgery (P < 0.05) and white blood cell count (WBC) 2 day post-surgery (P < 0.01) in IBS3 group were significantly higher compared with the AB3 group. Additionally, when IBS cost was 230 USD per set, the total blood transfusion cost in the IBSs groups was significantly higher than that in the ABs groups (P < 0.01); however, when 199 or 184 USD, only the IBS1 group, rather than IBS2 or IBS3, showed significantly higher cost of the total blood transfusion compared with the AB1 group (P < 0.05).
When the amount of bleeding was 600-1000 ml, IBS can significantly reduce the demand for allogeneic blood, and has no direct adverse effects on coagulation function and recuperation, and is cost-effective in OPCABG.
我们旨在评估术中血液回收(IBS)在不同出血量的非体外循环冠状动脉旁路移植术(OPCABG)中的安全性、有效性和成本效益。
我们回顾性分析了2012年12月至2016年12月在我院接受OPCABG手术的321例患者的病历。接受IBS或异体输血(AB)治疗的患者根据出血量分别分为三组:IBS1或AB1组(400 - 600毫升);IBS2或AB2组(600 - 1000毫升);IBS3或AB3组(1000 - 1500毫升)。检查术中及术后情况、输血量、临床和血液学结果以及总输血成本。
IBS组异体红细胞(RBC)输血量显著低于AB组(P < 0.01)。此外,与AB3组相比,IBS3组术后24小时引流量(P < 0.05)和术后2天白细胞计数(WBC)(P < 0.01)显著更高。此外,当IBS每套成本为230美元时,IBS组的总输血成本显著高于AB组(P < 0.01);然而,当成本为199或184美元时,只有IBS1组,而非IBS2或IBS3组,与AB1组相比总输血成本显著更高(P < 0.05)。
当出血量为600 - 1000毫升时,IBS可显著减少异体血需求,且对凝血功能和恢复无直接不良影响,在OPCABG中具有成本效益。